INTRODUCTION
Asparaginase is a critical agent in the treatment of acute lymphoblastic leukemia (ALL). This enzyme deaminates asparagine and glutamine, interfering with protein synthesis and resulting in cell death as lymphoblasts are deficient in asparagine synthetase. 1, 2 Native Escherichia coli (E coli) L-asparaginase and a pegylated version thereof, pegaspargase (SS-PEG), are major components of ALL treatment regimens. SS-PEG is currently the first-line asparaginase preparation used in Children's Oncology Group (COG) ALL trials.
Calaspargase pegol (SC-PEG) is a newly developed form of pegylated asparaginase that uses the identical enzyme and polyethylene glycol moiety present in SS-PEG; however, SC-PEG uses a succinimidyl carbonate linker that is more stable than the SS-PEG succinimidyl succinate linker. Specifically, SC-PEG urethane linkages formed with lysine groups are more hydrolytically stable.
3 SC-PEG and SS-PEG have comparable pharmacokinetic (PK) and pharmacodynamics (PD) properties in preclinical studies. 3 
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COG AALL07P4 was designed to assess the PK and PD comparability 4 of SC-PEG to SS-PEG when administered intravenously during induction and consolidation therapy in newly diagnosed patients with National Cancer Institute-designated high-risk (HR) B-cell ALL receiving an otherwise identical COG augmented Berlin-FrankfurtMünster (aBFM) -based chemotherapy regimen.
PATIENTS AND METHODS

Patients
Eligible patients (age 1 to 30.99 years) had newly diagnosed HR B-cell ALL (age Ն 10 years and/or initial WBC count Ն 50,000/microliter).
5 Key exclusion criteria included patients with Down syndrome, testicular leukemia, prior cytotoxic chemotherapy, pregnancy, and breastfeeding women. Institutional review board approval was obtained at each participating institution before patient enrollment. Written informed consent and assent (where appropriate) were obtained from each patient and/or his or her parent or guardian before initiation of therapy.
Study Design
This pilot multicenter, open-label, randomized trial opened to accrual in July 2008 at 23 COG centers. All patients received a modified COG aBFM chemotherapy regimen based on Children's Cancer Group 1961 arm C, 6 with the asparaginase preparation assigned at study enrollment. Patients were initially randomly assigned at a ratio of 2:1 to SC-PEG 2,500 IU/m 2 (SC-PEG2500; calaspargase pegol [EZN-2285]) versus SS-PEG (SS-PEG2500; pegaspargase). The regimens included a total of seven, 11, or 12 scheduled doses, depending on rapid early responders (RERs), slow early responders (SERs), and extended induction status, respectively, in the first 7 to 11 months of therapy ( Table 1) .
The primary end point was to determine the PK comparability 4 of SC-PEG and SS-PEG administered intravenously during induction and consolidation. Secondary end points included: safety, serum and CSF asparagine levels, immunogenicity, end-induction minimal residual disease (MRD), percentage of patients who were RERs, and complete remission and event-free survival rates. MRD was determined by multiparameter flow cytometry performed in a central laboratory. 7, 8 A cutoff of Ͻ 0.1% was used for treatment stratification; however, for outcome analysis, positive MRD was defined as Ն 0.01%, because multivariable analyses found this to be the most important prognostic variable in other COG trials. 9 Patients with Ͻ 5% blasts by morphologic bone marrow analysis on day 8 or 15 and day 29 and MRD Ͻ 0.1% were RERs; all others were SERs. The area under the curve (AUC) of asparaginase was based on plasma asparaginase activity from time 0 to 25 days (AUC 0-25 days ) after induction day-4 dose of study drug (mIU ϫ hr/mL) and was calculated using linear trapezoidal summation. The PK-evaluable analysis population was defined as patients who received 94% to 106% of the induction day-4 asparaginase dose and had samples available to calculate AUC 0-25 days . Additional PK parameters examined the percentage of patients with asparaginase activity Ն 100 and Ն 400 mIU/mL at specified time points. After planned interim PK analysis, the trial was amended in September 2009 to randomly assign patients between SC-PEG 2100 IU/m 2 (SC-PEG2100) versus SS-PEG2500, because this dose was predicted to achieve comparability of AUC 0-25 days . In December 2010, after data safety monitoring committee review of MRD suggested inferior results with SC-PEG2100, having crossed predefined response monitoring boundaries, the trial was closed to accrual.
Patients in the SC-PEG2100 arm were nonrandomly changed to SS-PEG2500 for the duration of therapy. In January 2011, results of COG AALL0232, conducted in an identical risk group of patients with ALL, demonstrated the superiority of high-dose methotrexate over Capizzi methotrexate in interim maintenance, 10 and the protocol was amended to incorporate this change. Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; version 3.0) before July 2011 and converted into CTCAE (version 4.0) codes, with subsequent AEs collected in CTCAE (version 4.0).
Laboratory Tests
PKs, PDs, and immunogenicity were performed at central laboratories (Frontage Laboratories, Malvern, PA, and Commonwealth Biotechnologies, Richmond, VA) at specified time points. PKs were determined by a validated enzymatic coupled activity-modified assay.
11 PDs were determined using validated reverse-phase high-performance liquid chromatography with double mass spectrometry. Immunogenicity assessment included the detection of both binding antibodies and neutralizing antibodies, determined by a validated direct enzyme-linked immunosorbent assay and an enzymatic coupled activity assay, respectively (Data Supplement).
Statistical Analysis
ClinicaldatafrozenasofSeptember30,2012,areincludedinthisreport.This report focuses on PK, PD, and AE data up to the end of delayed intensification I, and all patients were past that point in therapy as of that date. All analyses of clinical data were performed by intention to treat using validated SAS software (version 9.2; SAS Institute, Cary, NC).
2 and Fisher's exact tests were used for comparison of proportions between the three randomly assigned cohorts. All continuous data were summarized using medians and were compared among the three cohorts using the nonparametric Kruskal-Wallis test. The PK and PD data were computed from individual asparaginase activity and asparagine concentrations by applying a noncompartmental model approach using Phoenix WINNonlin software (version 6.1; Scientific Consultant, Apex, NC; Pharsight Corporation, St Louis, MO). For maximum plasma concentration (C max ) and AUC values (AUC 0-t , AUC 0-25 days , and AUC 0-), 90% CIs were calculated. For other parameters, the differences were described descriptively.
RESULTS
Patient Characteristics
Between October 2008 and December 2010, 166 patients were enrolled and randomly assigned (Fig 1) . One patient was inevaluable 
PK evaluable (n = 62) 
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www.jco.org because of a major protocol violation and was excluded. Three patients discontinued the trial before receiving the randomly assigned study drug, and 162 received treatment with the randomly assigned study drug. Demographic characteristics (Table 2 ) of the three groups were similar, except for a higher percentage of female patients in the SC-PEG2500 arm as compared with the SC-PEG2100 and SS-PEG arms (67% v 45% and 43%, respectively; P ϭ .04).
PKs
Mean plasma asparaginase activity versus asparagine concentration over time during induction and consolidation therapies is shown in Figure 2 . After completion of the induction day-4 intravenous dose of asparaginase, high levels of plasma asparaginase activity were observed for all treatment arms 5 minutes after infusion. Mean plasma asparaginase activity in all arms decreased based on the respective half-lives (t 1/2 ; Table 3 ). By 18 days after administration, patients treated with SC-PEG maintained higher levels of asparaginase activity when compared with SS-PEG-treated patients (Fig 2A) . Before the consolidation day-15 dose, which is at least 46 days after the induction day-4 asparaginase dose, 20% to 30% of patients in both SC-PEG groups had asparaginase activity Ն 100 mIU/mL, as compared with none in the SS-PEG group.
Similar to induction, after the day-15 consolidation dose ( Fig  2B) , high levels of plasma asparaginase activity were observed for all treatment arms at 5 minutes afater infusion; these decreased based on their respective t 1/2 (Table 3) . Twenty-one days after administration, patients treated with SC-PEG maintained higher levels of asparaginase activity when compared with SS-PEG-treated patients, and at 28 days after dosing, mean SS-PEG plasma asparaginase activity was below the therapeutic threshold of 100 mIU/mL, whereas those in the SC-PEG2100 and SC-PEG2500 groups had mean values of 333.8 and 412.9 mIU/mL, respectively.
PK results for the PK-evaluable patients for induction and consolidation are summarized in Table 3 . Mean t 1/2 of plasma asparaginase activity for both the SC-PEG doses was approximately 2.5ϫ longer than that of SS-PEG2500 in induction and consolidation.
When administered at the 2,500 IU/m 2 dose, the total systemic exposure to SC-PEG, as defined by induction AUC 0-25 days (404 IU ϫ h/mL) and AUC 0-inf (574 IU ϫ h/mL), was greater than that observed with SS-PEG2500 (365 and 387 IU ϫ h/mL, respectively). For SC-PEG2500 compared with SS-PEG2500, the ratio of geometric means and corresponding 90% CIs for AUC 0-25 days was 111.0% (90% CI, 100.7% to 122.3%). This difference in total systemic exposure as defined by Induction AUC 0-25 days was not seen with SC-PEG2100 group. A similar pattern of C max , t 1/2 , systemic exposure, and elimination constant was also observed during consolidation (Table 3) . Plasma asparaginase activity presented as the percentage of PKevaluable patients with asparaginase activity Ն 100 and Ն 400 mIU/mL by treatment group during induction and consolidation is shown in Figure 3 . During induction, SS-PEG2500 and both doses of SC-PEG achieved comparable results in the proportion of patients who maintained asparaginase activity levels Ն 100 mIU/mL through 18 days after the induction dose. Twenty-five days after the induction dose, both doses of SC-PEG maintained asparaginase activity levels Ն 100 mIU/mL in 95% of patients, as compared with only 28.6% of patients receiving SS-PEG2500 (Fig 3A; P Ͻ .001) . By the time of the first consolidation dose of asparaginase (approximately 46 days after induction dose), approximately one quarter of the patients receiving SC-PEG continued to have asparaginase activity levels Ն 100 mIU/ mL, whereas no patients in the SS-PEG2500 arm did (P ϭ .002).
Using an asparaginase activity threshold level of Ն 400 mIU/ mL, both SC-PEG2500 and SS-PEG2500 achieved comparable results in the proportion of patients who maintained this level through 11 days, with SC-PEG2100 being slightly lower. After that time point, the proportion of patients maintaining a level of asparaginase activity Ն 400 mIU/mL was higher for both doses of SC-PEG compared with SS-PEG2500. By the end of induction, none of the SS-PEG2500 patients maintained asparaginase activity level Ն 400 mIU/mL, compared with 27.5% in the SC-PEG2500 group and 13.6% in the SC-PEG2100 group (P Ͻ .001). During consolidation (Fig 3B) , results were observed similar to those seen during the induction phase.
PDs
There was a direct correlation between the reduction in plasma asparagine and plasma asparaginase activity during induction and consolidation (Figs 2A and 2B ). Plasma asparagine was completely reduced with higher levels of asparaginase activity and began to rebound once plasma asparaginase activity declined Ͻ 400 mIU/mL. Thus, the longer t 1/2 of SC-PEG resulted in a prolonged suppression of plasma asparagine.
Baseline mean plasma asparagine concentrations were similar for all three groups. After the induction dose, plasma asparagine concentrations decreased and were not detectable (Ͻ 0.05 g/mL) for all treatment groups at the 5 minutes postdose time point and remained undetectable for 11 days for SS-PEG2500 and 18 days for both SC-PEG groups. Twenty-five days after administration, plasma asparagine levels were undetectable in some patients in all three groups (88%, 95%, and 96% in SS-PEG2500, SC-PEG2500, and SC-PEG2100 groups, respectively). After this time point, the rate of plasma asparagine rise was greatest in the SS-PEG group.
Before consolidation day-15 dosing, the residual plasma asparagine level in patients in the SS-PEG2500 group was 5.33 g/mL (72.4% of preinduction baseline, with only 3% of patients Ͻ lower limit of detection [LLD] ). By comparison, the residual plasma asparagine levels in patients treated with SC-PEG2500 and SC-PEG2100 were 0.64 (7.6% of preinduction baseline, with 72% of patients Ͻ LLD) and 0.88 g/mL (11.8% of preinduction baseline, with 76% of patients Ͻ LLD), respectively. Similar levels were observed after the consolidation dose.
CSF Asparagine Concentration
Mean CSF asparagine concentration by treatment group during induction and consolidation is shown in Figure 2C . All three treatment regimens were effective in reducing CSF asparagine levels. Four days after the induction dose, mean CSF asparagine concentration in all treatment groups was diminished to approximately 25% to 30% of the preinduction dose values. Mean CSF asparagine levels returned to prebaseline levels by the time of the consolidation dose on day 15 in SS-PEG2500 -treated patients, which was earlier than occurred for SC-PEG-treated patients (60% of baseline in SC-PEG2500 group; 40% of baseline in SC-PEG2100 group). 
Immunogenicity
Antiasparaginase binding antibodies were confirmed in eight patients: four in the SS-PEG2500 group, two in the SC-PEG2500 group, and two in the SC-PEG2100 group. None of these patients had positive neutralizing antibody assays; however, three patients treated with SS-PEG and one treated with SC-PEG2500 were noted to have more rapid clearance of asparaginase activity compared with their treatment groups. Two of these eight patients (one in SC-PEG2500 group and one in SC-PEG2100 group) had positive binding antibodies in the preinduction dose sample and had no subsequent positive tests, and no effect on asparaginase activity was seen. One SC-PEG2100 patient was noted to have a neutralizing antibody to SC-PEG and a false-positive binding assay but was noted to have more rapid clearance of asparaginase activity. In the patients with positive binding antibodies, allergic or hypersensitivity reactions were reported in two of four SS-PEG2500 patients, one of two SC-PEG2500 patients, and no patients in the SC-PEG2100 group.
Asparaginase-Specific AEs
Protocol-specified asparaginase-specific AEs (regardless of grade or attribution to study drug; allergic reactions, coagulopathy, hyperbilirubinemia, hyperglycemia, hyperlipidemia, ketoacidosis, pancreatitis, thrombosis, and CNS events [bleeding, thrombosis, or infarction]) are listed in Table 4 . AEs were similar between the three different treatment arms, with the exception of hyperglycemia in induction and hyperbilirubinemia in delayed intensification I, which were higher for the SC-PEG groups than for the SS-PEG2500 group (P ϭ .001 and .01, respectively). When restricted to grade 3 and 4 events, the incidence of hyperbilirubinemia in delayed intensification I was not significant (P ϭ .71; Appendix Table A1 , online only).
End-of-Induction Treatment Response
The end-of-induction treatment responses are listed in Table 2 . The rates of RERs and MRD negativity were similar in the SC-PEG2500 (82% and 74%, respectively) and SS-PEG2500 groups (76% and 72%, respectively). However, the SC-PEG2100 group had a lower rate of RERs and MRD negativity (65% and 56%, respectively) compared with the SC-PEG2500 treatment group (P ϭ .15 and .18, respectively). Although these differences were not statistically significant, at the time of interim analysis, the available values had crossed predefined response monitoring boundaries, leading to suspension of enrollment and transition of all SC-PEG2100 patients to SS-PEG2500. 
DISCUSSION
L-asparaginase is an essential component of standard combination therapy for ALL, and most children with ALL treated in North America and Western Europe now receive SS-PEG. 12 This study investigated a new formulation of pegylated asparaginase conjugated with a more stable SC linker that also imparts improved drug product shelf life compared with SS-PEG. 3 Early studies in nonhuman primates as well as previously published reports have concluded that Ն 100 mIU/mL is an appropriate target level of asparaginase activity associated with asparagine depletion when a native asparaginase is used. [13] [14] [15] [16] Some reports have noted that complete asparagine depletion can still be observed even with levels Ͻ 100 mIU/mL. 17, 18 Other investigators have suggested that a higher level of asparaginase activity (Ն 400 mIU/mL) is needed to achieve optimal asparagine depletion. 19 Our data suggest that asparaginase activity level Ն 400 mIU/mL is associated with more significant asparagine depletion, which could translate to improved outcomes. We found that SC-PEG2500 was comparable in PKs to SS-PEG2500 with regard to AUC 0-25 days and C max , whereas SC-PEG2100 was comparable in PKs to SS-PEG2500 with regard to AUC 0-25 days . The t 1/2 of asparaginase activity for both doses of SC-PEG was more than twice that of SS-PEG2500. After a single infusion at day 4, both SC-PEG doses were effective in maintaining asparaginase activity Ն 100 mIU/mL in Ͼ 95% of patients at the end of the 4-week induction phase, and 20% to 30% of patients still had levels above this threshold 3 weeks later (consolidation day 15). By comparison, Ͻ 30% of patients treated with SS-PEG2500 maintained asparaginase activity Ն 100 mIU/mL at end of induction, and none had levels above this threshold at consolidation day 15. Similarly, patients treated with SC-PEG maintained asparaginase activity level Ն 400 mIU/mL for longer than those who received SS-PEG2500. Both doses of SC-PEG were effective in reducing plasma asparagine levels below detectable levels for a longer duration than SS-PEG2500 during induction and consolidation.
End-of-induction complete remission rates, RERs, and MRD negativity were similar among the three groups. However, the SC-PEG2100 group trended toward inferior responses, with lower rates of RERs and MRD negativity (65% and 56%, respectively) compared with the SS-PEG and SC-PEG2500 groups. This difference crossed predefined statistical monitoring boundaries during conduct of the study, but ultimately, it was not statistically significant. The reason for this difference is unclear and may be an artifact resulting from small sample size or the higher number of older patients in the SC-PEG2100 group (P ϭ .13). Superior responses might be explained by enhanced asparagine depletion having an effect on the clearance of leukemia blasts. There was a slightly higher percentage of patients age Ն 16 years in the SC-PEG2100 group as compared with the other two groups, which did not reach conventional levels of statistical significance (P ϭ .06), and older adolescents have been shown to have inferior end-of-induction MRD responses compared with younger patients with HR B-cell ALL, 20 but this likely does not fully explain the observed differences.
Few patients in all groups had confirmed antiasparaginase antibodies, even though clinical allergic or hypersensitivity reactions were reported at a higher rate. Half of patients with antiasparaginase antibodies did not have clinical allergic or hypersensitivity reactions reported, and numerous patients had allergic or hypersensitivity reactions reported but no antibodies detected. This may be because of assay limitations. Some of the reported allergic reactions may have actually been allergic or hypersensitivity reactions related to other medications or blood products or nonallergic infusion reactions.
The limitations of this study include small numbers of patients, the challenge of measuring plasma asparagine in the presence of ex vivo asparaginase activity, and possibly reporting bias in this openlabel trial. Although COG phase III studies do not require reporting of grade 1 or 2 AEs, for this trial, the US Food and Drug Administration mandated reporting of asparaginase-specific events of all grades regardless of attribution; thus, the rates attributed to asparaginase may have been overestimated and cannot be compared directly with those from other COG ALL trials.
COG AALL07P4 randomly assigned patients with newly diagnosed HR B-cell ALL at a 2:1 ratio to receive SC-PEG (2100 or 2500 IU/m 2 ) or SS-PEG (2,500 IU/m 2 ) during aBFM multiagent chemotherapy. Because of its increased t 1/2 , SC-PEG2500 produced a significantly longer period of asparagine depletion than SS-PEG2500 and had a comparable toxicity profile in children with HR B-cell ALL. Additional studies are needed to determine whether the superior PK and PD properties of SC-PEG translate to improved treatment outcomes. 
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